Clinical Trials Browser

Phase 2 × Blast Crisis × Arsenic Trioxide × Clear all

NCT00003885 2013-11-06

Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Blast Crisis, Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

NCT00005618 2013-06-21

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia

Phase 2 Completed

Other hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

NCT00006092 2012-09-26

Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia

Phase 2 Terminated

2 enrolled

LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Lymphoid, Leukemia, Monocytic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma